{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:10:04Z","timestamp":1778944204750,"version":"3.51.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014489","name":"Johnson & Johnson Pharmaceutical Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102538","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:30:59Z","timestamp":1773250259000},"page":"102538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration\u2013Sensitive Prostate Cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"Federico","family":"Losco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Villareal Trujillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis Leonardo","family":"Jardim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Rodr\u00edguez-Covarrubias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Perich\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Martins da Trindade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Villoldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Neciosup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9ctor","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Ibat\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Mart\u00ednez-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-9741","authenticated-orcid":false,"given":"Ray Manneh","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG AFU 15): a randomised, open label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2026.102538_bib0002","doi-asserted-by":"crossref","first-page":"CT190","DOI":"10.1158\/1538-7445.AM2021-CT190","article-title":"Latin American patient subgroup analysis of the phase 3 TITAN study","volume":"81","author":"Juarez","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.clgc.2026.102538_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820915720","article-title":"Prostate cancer in Latin America: challenges and recommendations","volume":"27","author":"Reis","year":"2020","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.clgc.2026.102538_bib0004","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ijc.32749","article-title":"Cancer mortality predictions for 2019 in Latin America","volume":"147","author":"Carioli","year":"2020","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2026.102538_bib0005","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.4067\/S0034-98872022001001370","article-title":"Mortalidad por c\u00e1ncer de pr\u00f3stata en Chile: tendencias 1955\u20132019","volume":"150","author":"L\u00f3pez","year":"2022","journal-title":"Rev Med Chil"},{"issue":"13","key":"10.1016\/j.clgc.2026.102538_bib0006","first-page":"3184","article-title":"Incidence, mortality, and trends of prostate cancer in Mexico 2000\u20132019","volume":"14","author":"Beltran Ontiveros","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.clgc.2026.102538_bib0007","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/cancers11091355","article-title":"Current treatment options for metastatic hormone sensitive prostate cancer","volume":"11","author":"Cattrini","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clgc.2026.102538_bib0008","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","article-title":"Treatment patterns and outcomes in metastatic castration resistant prostate cancer in a Real-world Clinical Practice Setting in the United States","volume":"18","author":"George","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102538_bib0009","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.2147\/JPR.S371337","article-title":"The burden of metastatic cancer\u2013induced bone pain","volume":"15","author":"Colosia","year":"2022","journal-title":"J Pain Res"},{"key":"10.1016\/j.clgc.2026.102538_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.555475","article-title":"Cardiovascular complications of prostate cancer treatment","volume":"11","author":"Wilk","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102538_bib0011","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11934-015-0488-8","article-title":"Management of metastatic hormone sensitive prostate cancer","volume":"16","author":"Bernard","year":"2015","journal-title":"Curr Urol Rep"},{"issue":"11","key":"10.1016\/j.clgc.2026.102538_bib0012","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S1470-2045(19)30628-X","article-title":"Quality of life in metastatic hormone sensitive prostate cancer","volume":"20","author":"Chambers","year":"2019","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.clgc.2026.102538_bib0013","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.3390\/cancers16183187","article-title":"Strategic advances in combination therapy for mCSPC","volume":"16","author":"Kwon","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.euf.2018.12.003","article-title":"Health care delivery for metastatic hormone-sensitive prostate cancer across the globe","volume":"5","author":"Herlemann","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.clgc.2026.102538_bib0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0016","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102538_sbref0017","series-title":"NCCN Guidelines\u00ae Insights: Prostate Cancer","author":"Schaeffer","year":"2024"},{"issue":"17","key":"10.1016\/j.clgc.2026.102538_bib0018","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum imaging strategies for advanced prostate cancer: ASCO guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102538_bib0019","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102538_bib0020","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102538_bib0021","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"10162","key":"10.1016\/j.clgc.2026.102538_bib0022","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0023","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.juro.2018.08.050","article-title":"The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial","volume":"201","author":"Andriole","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102538_bib0024","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00345-018-2236-4","article-title":"The impact of time to metastasis on overall survival in patients with prostate cancer","volume":"36","author":"Frees","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2026.102538_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ctrv.2018.08.005","article-title":"De novo metastatic castration sensitive prostate cancer: state of art and future perspectives","volume":"70","author":"Mosillo","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.clgc.2026.102538_bib0026","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CGC.2003.n.011","article-title":"Ten-year survival in patients with metastatic prostate cancer","volume":"2","author":"Tangen","year":"2003","journal-title":"Clin Prostate Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102538_bib0027","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.clon.2017.08.003","article-title":"Prostascore: a simplified tool for predicting outcomes among patients with treatment-naive advanced prostate cancer","volume":"29","author":"Abdel-Rahman","year":"2017","journal-title":"Clin Oncol"},{"issue":"15","key":"10.1016\/j.clgc.2026.102538_bib0028","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102538_bib0029","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102538_bib0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5489\/cuaj.8588","article-title":"2023 Canadian Urological Association guideline: genetic testing in prostate cancer","volume":"17","author":"Rendon","year":"2023","journal-title":"Can Urol Assoc J"},{"issue":"14","key":"10.1016\/j.clgc.2026.102538_bib0031","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102538_bib0032","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","article-title":"The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer","volume":"20","author":"Lee","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0033","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.bjc.6604453","article-title":"Rapid progression of prostate cancer in men with a BRCA2 mutation","volume":"99","author":"Narod","year":"2008","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2026.102538_bib0034","doi-asserted-by":"crossref","first-page":"e1042","DOI":"10.1634\/theoncologist.2019-0495","article-title":"Prognostic value of germline DNA repair gene mutations in de novo metastatic and castration-sensitive prostate cancer","volume":"25","author":"Wei","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2026.102538_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"1","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2026.102538_bib0036","doi-asserted-by":"crossref","DOI":"10.1200\/GO-24-00319","article-title":"Surgical castration as an alternative to improve systemic treatment for advanced prostate cancer: a window of opportunity for developing countries","author":"Monteiro","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.clgc.2026.102538_bib0037","doi-asserted-by":"crossref","unstructured":"Kunath F, Jensen K, Pinart M, et al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 019;6:CD003506. https:\/\/doi.org\/10.1002\/14651858.CD003506.pub2","DOI":"10.1002\/14651858.CD003506.pub2"},{"issue":"3","key":"10.1016\/j.clgc.2026.102538_bib0038","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urology.2009.08.008","article-title":"Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?","volume":"75","author":"Oh","year":"2010","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.clgc.2026.102538_bib0039","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2026.102538_bib0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0041","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102538_bib0042","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102538_bib0043","doi-asserted-by":"crossref","unstructured":"Agarwal N, McQuarrie K, Bjartell A, et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncol.;20(11):1518-28. https:\/\/doi.org\/10.1016\/S1470-2045(19)30620-5","DOI":"10.1016\/S1470-2045(19)30620-5"},{"issue":"20","key":"10.1016\/j.clgc.2026.102538_bib0044","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med."},{"issue":"10393","key":"10.1016\/j.clgc.2026.102538_bib0046","first-page":"1259","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"401","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.clgc.2026.102538_bib0047","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clgc.2026.102538_bib0048","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.clgc.2026.102538_bib0049","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10024","key":"10.1016\/j.clgc.2026.102538_bib0050","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"10336","key":"10.1016\/j.clgc.2026.102538_bib0051","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clgc.2026.102538_bib0052","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102538_bib0053","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive Prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102538_bib0054","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102538_bib0055","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer: systematic review, network meta-analysis, and benefit-harm assessment","volume":"5","author":"Menges","year":"2022","journal-title":"Eur Urol Oncol."},{"issue":"29","key":"10.1016\/j.clgc.2026.102538_bib0056","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10185","key":"10.1016\/j.clgc.2026.102538_bib0057","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.clgc.2026.102538_bib0058","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102538_bib0059","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2026.102538_bib0060","unstructured":"Instituto de Investigaci\u00f3n en Oncolog\u00eda Radioter\u00e1pica \u2013 Fundaci\u00f3n Espa\u00f1ola de Oncolog\u00eda Radioter\u00e1pica. Phase III Study of Stereotactic Body Radiation Therapy (SBRT) plus Standard of Care in Castration-sensitive Oligometastatic Prostate Cancer Patients (START-MET). ClinicalTrials.gov Identifier: NCT05209243. https:\/\/clinicaltrials.gov\/study\/NCT05209243"},{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0061","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2026.102538_bib0062","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"10.1016\/j.clgc.2026.102538_bib0063","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician\u2019s guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.clgc.2026.102538_bib0064","doi-asserted-by":"crossref","first-page":"279","DOI":"10.11005\/jbm.2021.28.4.279","article-title":"Medication related osteonecrosis of the jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons","volume":"28","author":"Kim","year":"2021","journal-title":"J Bone Metab"},{"issue":"1","key":"10.1016\/j.clgc.2026.102538_bib0065","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1038\/s41598-020-62182-w","article-title":"Post-treatment levels of plasma 25-and 1, 25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer","volume":"10","author":"Nair-Shalliker","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.clgc.2026.102538_bib0066","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MOU.0000000000000101","article-title":"Androgen-deprivation-associated bone disease","volume":"24","author":"Skolarus","year":"2014","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102538_bib0067","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/bjc.2015.479","article-title":"Effects of a lifestyle intervention on endothelial function in men on long-term androgen deprivation therapy for prostate cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.clgc.2026.102538_bib0068","first-page":"5661","article-title":"The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review","volume":"28","author":"Edmunds","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2026.102538_bib0069","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1249\/MSS.0000000000002503","article-title":"Resistance exercise dosage in men with prostate cancer: systematic review, meta-analysis, and meta-regression","volume":"53","author":"Lopez","year":"2020","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"10.1016\/j.clgc.2026.102538_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263918","article-title":"The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: an update systematic review and meta-analysis","volume":"17","author":"Shao","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.clgc.2026.102538_bib0071","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41391-021-00450-0","article-title":"Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis","volume":"25","author":"Ussing","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.clgc.2026.102538_bib0072","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.euf.2018.02.007","volume":"5","author":"SD","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.clgc.2026.102538_bib0073","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/biomedicines13051132","article-title":"Current status and future perspectives of nuclear medicine in prostate cancer from imaging to therapy: a comprehensive review","volume":"13","author":"Lee","year":"2025","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.clgc.2026.102538_bib0074","first-page":"23","article-title":"Status of nuclear medicine in Latin America and the Caribbean: IAEA analysis of development in the past 6 years","volume":"62","author":"Orellana","year":"2021","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102538_bib0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12032-018-1105-8","article-title":"Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective","volume":"35","author":"Sade","year":"2018","journal-title":"Med Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:29:51Z","timestamp":1778941791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000388"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102538","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Latin American Consensus for the Diagnosis and Treatment of Metastatic Castration\u2013Sensitive Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102538"}}